Effect of remazolam toluenesulfonate on postoperative cognitive function in patients undergoing cardiac surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092938

Enrollment

Unknown

Registered

2024-11-26

Start date

2024-12-02

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Remimazolam:Remidazolam 0.1-0.3mg/kg was given intravenously

Propofol:Propofol 0.1-0.3mg/kg was given intravenously

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 60 years old; 2. Patients undergoing cardiac valve replacement surgery; 3. American Society of anesthesiologists (ASA) grade ? ~ ?; 4. Preoperative MMSE score >= 24.

Exclusion criteria

Exclusion criteria: 1. Combined with mental disease and nervous system disease; 2. Combined with heart, liver and kidney dysfunction; 3. Recent use of psychotropic drugs.

Design outcomes

Primary

Measure	Time frame
The incidence of postoperative cognitive dysfunction;	—

Secondary

Measure	Time frame
cerebral regional oxygen saturation;S100 ß;TNF-a;IL-6;IL-1ß;	—

Countries

China

Contacts

Public ContactWen Huaichang

The First Affiliated Hospital of Wannan Medical College

wenhc19851207@163.com+86 136 9656 8215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026